Opioid Use Disorder Research Study
Researchers at Johns Hopkins University are conducting a study to evaluate suvorexant for sleep disturbance in opioid use disorders.
Fast Facts
Ages 18-65 and Diagnosed with Opioid Use Disorder
Currently Dependent on Opioids Including Fentanyl
Not Using Buprenorphine, Suboxone, Methadone, or Naltrexone
Compensation Provided
Conducted in Baltimore, MD
Study Background
Johns Hopkins University is looking for individuals diagnosed with opioid use disorder who are currently dependent on opioids including fentanyl, and are interested in maintaining buprenorphine use.
This clinical research study is evaluating if a sleep medication (suvorexant) is effective in alleviating sleep disturbance and improving treatment outcomes for individuals initiating buprenorphine maintenance.
Participants will attend a screening visit, followed by 5 day residential and 3 weeks outpatient treatment. The duration of the study is about four weeks.
If you are currently dependent on opioids (including heroin or fentanyl) and are not using buprenorphine, suboxone, methadone, or naltrexone as treatment for your opioid use, you may qualify to participate. Further research and join our compensated study!
Study Background
Johns Hopkins University is looking for individuals diagnosed with opioid use disorder who are currently dependent on opioids including fentanyl, and are interested in maintaining buprenorphine use.
This clinical research study is evaluating if a sleep medication (suvorexant) is effective in alleviating sleep disturbance and improving treatment outcomes for individuals initiating buprenorphine maintenance.
Participants will attend a screening visit, followed by 5 day residential and 3 weeks outpatient treatment. The duration of the study is about four weeks.
If you are currently dependent on opioids (including heroin or fentanyl) and are not using buprenorphine, suboxone, methadone, or naltrexone as treatment for your opioid use, you may qualify to participate. Further research and join our compensated study!
Additional Information
The purpose of this research study is to evaluate suvorexant for sleep disturbance in opioid use disorders.
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18-65
- Diagnosed with opioid use disorder and dependent on opioids
- Currently dependent on opioids including fentanyl
- Not using buprenorphine, suboxone, methadone, or naltrexone as treatment for your opioid use
- Interested in maintaining buprenorphine use
- No severe alcohol, benzodiazepine, or stimulant use disorder
- Not taking benzodiazepines or other prescribed medications for insomnia
- No narcolepsy, restless leg syndrome, or sleep paralysis
- Able to take buprenorphine, sublocade, or suvorexant
- No suicidal ideation
- Have a stable living situation
- No hepatic or renal impairment
- If female, not pregnant or breastfeeding
- Currently taking >8mg of buprenorphine
Once enrolled, this study involves:
- Screening visit
- Residential Phase (5 days)
- Receive a maintenance dose of buprenorphine
- Complete sleep assessments
- Monitor opioid withdrawal, craving, and other outcomes 4x daily
- Outpatient Phase (3 weeks)
- Continue buprenorphine
- Assess sleep via ambulatory monitoring
- Monitor opioid-related withdrawal and craving
Compensation is provided up to $1130 for your participation.
There is no cost for you to participate in our research study.
